Clinical trials: Peripheral Arterial Obstructive Disease
Peripheral Arterial Diseases
Actovegin 12-Week Treatment Given First Intravenously and Subsequently Orally in Participants With Peripheral Arterial Occlusive Disease Fontaine Stage IIB
The purpose of the study is to evaluate the efficacy and safety of actovegin in participants with peripheral arterial disease (PAD) Fontaine Stage IIB.
- Trial name
- APOLLO (NCT03469349)
- Testing
- Actovegin
- Where
- 20 sites in Georgia, Kazakhstan and 1 more
- Volunteers
- 366 people
- Sponsor
- Takeda
Peripheral Artery Disease
Study of PVS-10200 for the Treatment of Restenosis in Patients With Peripheral Artery Disease (TRIUMPH)
The purpose of this study is to evaluate the safety of two doses of PVS-10200, an allogeneic cellular therapy, delivered as a single injection following percutaneous transluminal ("balloon") angioplasty and stent placement for…
- Trial name
- TRIUMPH (NCT01099215)
- Testing
- PVS-10200
- Where
- 3 sites in France
- Volunteers
- 21 people
- Sponsor
- Shire
Peripheral Arterial Disease
Supervised Treadmill Exercise and Ranolazine for Intermittent Claudication of Lower Extremities
The goal of this study is to evaluate whether supervised treadmill exercise combined with ranolazine 1000 mg twice daily provides an incremental benefit in absolute walking distance over supervised exercise alone in patients with…
- Trial name
- STERILE (NCT00914316)
- Testing
- Ranolazine
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Corewell Health East
Peripheral Vascular Diseases
Evaluation of the Zilver PTX Drug-Eluting Stent in the Above-the-Knee Femoropopliteal Artery
The Zilver® PTX™ Drug Eluting Vascular Stent is indicated for the treatment of symptomatic vascular disease of the above-the-knee femoropopliteal artery (ranging from 4 mm to 9 mm in reference vessel diameter) for lesions up to 7…
- Trial name
- Zilver PTX (NCT00120406)
- Testing
- Zilver® PTX™ Drug Eluting Vascular Stent, Angioplasty
- Where
- 52 sites in United States, Germany and 1 more
- Volunteers
- 474 people
- Sponsor
- Cook Group Incorporated
Peripheral Artery Disease
Nicotinamide Riboside With and Without Resveratrol to Improve Functioning in Peripheral Artery Disease
NICE is a randomized clinical trial that will examine the effects of nicotinamide riboside (NR) both with and without resveratrol to test whether, among people with PAD, NR significantly improves walking performance more than…
- Trial name
- NICE (NCT03743636)
- Testing
- Nicotinamide riboside, Resveratrol
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- Northwestern University
Peripheral Arterial Disease, Claudication (Finding)
Cilostazol After Lower Extremity Arterial Revascularization Trial
Twenty patients will be recruited to CLEAR. Ten will be randomized to the treatment arm (Cilostazol) and tenwill be randomized to the control group. Patients randomized to the treatment arm will receive Cilostazol for 90 days.
- Trial name
- CLEAR (NCT02374957)
- Testing
- Cilostazol
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Wake Forest University Health Sciences
Peripheral Arterial Disease, Peripheral Vascular Disease
Safety and Efficacy of the SurVeil™ Drug-Coated Balloon
To demonstrate the safety and efficacy of the SurVeil Drug-Coated Balloon (DCB) for treatment of subjects with symptomatic peripheral artery disease (PAD) due to stenosis of the femoral and/or popliteal arteries.
- Conditions
- Peripheral Arterial Disease, Peripheral Vascular Disease, Artery Disease, Peripheral, Femoropopliteal Artery Occlusion
- Trial name
- TRANSCEND (NCT03241459)
- Testing
- Surmodics SurVeil DCB, Medtronic IN.PACT Admiral DCB
- Where
- 63 sites in United States, Australia and 7 more
- Volunteers
- 446 people
- Sponsor
- SurModics, Inc.
Prevention & Control
Rivaroxaban for the Prevention of Major Cardiovascular Events in Coronary or Peripheral Artery Disease
The primary objectives of this study are: To determine whether rivaroxaban 2.5 mg twice daily (bid) + aspirin 100 mg once daily (od) compared with aspirin 100 mg od reduces the risk of a composite of myocardial infarction…
- Trial name
- COMPASS (NCT01776424)
- Testing
- Rivaroxaban (Xarelto, BAY59-7939), Aspirin, Pantoprazole
- Where
- 565 sites in United States, Argentina and 31 more
- Volunteers
- 27,395 people
- Sponsor
- Bayer
Peripheral Arterial Disease
Evaluation of the FreedomFlow™ Orbital Atherectomy System to Treat Peripheral Artery Disease
To evaluate the safety and effectiveness of the Cardio Flow FreedomFlow™ Orbital Circumferential Atherectomy System for atherosclerotic plaque removal and vessel compliance modification in de novo native target lesions in the…
- Trial name
- FASTII (NCT03635190)
- Testing
- Orbital Circumferential Atherectomy
- Where
- 13 sites in United States
- Volunteers
- 112 people
- Sponsor
- Cardio Flow, Inc.
Peripheral Artery Disease
Comprehensive Magnetic Resonance of Peripheral Arterial Disease
The purpose of this study is to develop new ways of imaging fatty blockages in the leg arteries to improve upon techniques used now and to develop new ways of understanding how new treatments may affect the disease.
- Trial name
- NCT00587678
- Testing
- Simvastatin, Ezetimibe, Simvastatin/Ezetimibe
- Where
- United States
- Volunteers
- 85 people
- Sponsor
- University of Virginia
Peripheral Artery Disease
Humacyte's HAV for Femoro-Popliteal Bypass in Patients With PAD
This study will evaluate how well Humacyte's Human Acellular Vessel (HAV) works when surgically implanted into a leg to improve blood flow in patients with peripheral arterial disease (PAD).
- Trial name
- NCT02887859
- Testing
- Human Acellular Vessel (HAV)
- Where
- 5 sites in United States
- Volunteers
- 15 people
- Sponsor
- Humacyte, Inc.
Peripheral Vascular Disease
The Complete® SE SFA Study for the Treatment of SFA/PPA Lesions
To evaluate the safety and efficacy of the Complete SE SFA Stent System in the treatment of de novo and/or restenotic lesions or occlusions in the Superficial Femoral Artery (SFA) and/or Proximal Popliteal Artery (PPA) in…
- Trial name
- NCT00814970
- Testing
- Complete SE Vascular Stent System
- Where
- 4 sites in United States
- Volunteers
- 196 people
- Sponsor
- Medtronic Endovascular
Peripheral Arterial Disease
Polestriding Versus Walking for Subjects With Poor Leg Circulation
The purpose of this study is to compare the effects of polestriding (walking with poles) and traditional walking on physical endurance in subjects with poor circulation in their legs.
- Trial name
- NCT00719355
- Testing
- Walking with poles, Walking exercise
- Where
- United States
- Volunteers
- 146 people
- Sponsor
- University of Illinois Chicago
Peripheral Artery Disease, Vascular Disease
In-Stent Restenosis Post-Approval Study
The objective of the ISR 14-04 study is to evaluate post-market safety and effectiveness of GORE® VIABAHN® Endoprosthesis for treatment of In-Stent Restenosis of the Superficial Femoral Artery.
- Trial name
- NCT02542267
- Testing
- Gore VIABAHN Endoprosthesis
- Where
- 23 sites in United States, Germany and 2 more
- Volunteers
- 108 people
- Sponsor
- W.L.Gore & Associates
Peripheral Artery Disease, Vascular Disease
Use of Autologous Concentrated Bone Marrow Aspirate in Preventing Wound Complications in Below Knee Amputation (BKA)
Patients scheduled for major extremity lower amputation to receive bone marrow cells (cBMA) injected IM in the leg proximal to the amputation in the index limb to prevent ischemic wound complications after surgery.
- Conditions
- Peripheral Artery Disease, Vascular Disease, Critical Limb Ischemia
- Trial name
- MarrowCHAMP (NCT02863926)
- Testing
- Injection of cBMA aspirate into the index leg
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Michael Murphy
Angioplasty, Transluminal, Percutaneous Coronary, Coronary Arteriosclerosis
Safety and Effectiveness Study of the Ensure Medical Vascular Closure Device
The purpose of this study is to determine whether the Ensure Medical Vascular Closure Device is more effective than standard manual compression at sealing the puncture made in the femoral artery following a cardiac or peripheral…
- Conditions
- Angioplasty, Transluminal, Percutaneous Coronary, Coronary Arteriosclerosis, Peripheral Arteriosclerosis
- Trial name
- NCT00345631
- Testing
- Manual Compression, Vascular Closure Device
- Where
- 17 sites in United States
- Volunteers
- 488 people
- Sponsor
- Cordis US Corp.
Coronary Artery Disease
Effect of Methylnaltrexone on the PK/PD Profiles of Ticagrelor in Patients Treated With Morphine
Ticagrelor is associated with more prompt and potent antiplatelet effects compared with clopidogrel, leading to better clinical outcomes, including reduced cardiovascular mortality, across the spectrum of patients with acute…
- Trial name
- NCT02403830
- Testing
- Methylnaltrexone, Morphine, Ticagrelor
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Florida
Chronic Obstructive Pulmonary Disease (COPD)
Effect of Rosuvastatin Therapy in Patients With Stable Chronic Obstructive Pulmonary Disease
The purpose of this study is to investigate whether rosuvastatin improves measures of endothelial function, decreases measures of inflammation, and improves pulmonary function in patients with stable chronic obstructive pulmonary…
- Trial name
- RODEO (NCT00929734)
- Testing
- Rosuvastatin
- Where
- Norway
- Volunteers
- 99 people
- Sponsor
- University Hospital, Akershus
Vitamin D Deficiency, Coronary Artery Disease
Vitamin D Repletion in Coronary Artery Disease
Vitamin D (Vit D) status is an emerging risk marker of great interest in cardiovascular disease (CVD). Lower serum levels of Vit D are associated with both cardiac risk factors and prevalent cardiovascular disease.
- Conditions
- Vitamin D Deficiency, Coronary Artery Disease, Endothelial Dysfunction, Inflammation
- Trial name
- NCT01570309
- Testing
- Ergocalciferol, Sugar pill
- Where
- 2 sites in United States
- Volunteers
- 96 people
- Sponsor
- Seth I. Sokol, M.D.
Peripheral Arterial Disease
Efficacy Evaluation of Dotarem Compared to Gadovist in the Diagnosis of Peripheral Arterial Disease
This study is an efficacy evaluation of Dotarem®-enhanced magnetic resonance angiography (MRA) compared to Gadovist®-enhanced MRA in the diagnosis of clinically significant abdominal or lower limb arterial diseases.
- Trial name
- DALIA (NCT01026389)
- Testing
- Dotarem, Gadovist
- Where
- Austria
- Volunteers
- 189 people
- Sponsor
- Guerbet